<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<!--The publisher of this article does not allow downloading of the full text in XML form.-->
<?properties manuscript?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-journal-id">8406521</journal-id>
<journal-id journal-id-type="pubmed-jr-id">6573</journal-id>
<journal-id journal-id-type="nlm-ta">Pharm Res</journal-id>
<journal-id journal-id-type="iso-abbrev">Pharm. Res.</journal-id>
<journal-title-group>
<journal-title>Pharmaceutical research</journal-title>
</journal-title-group>
<issn pub-type="ppub">0724-8741</issn>
<issn pub-type="epub">1573-904X</issn>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">31332533</article-id>
<article-id pub-id-type="pmc">6814258</article-id>
<article-id pub-id-type="doi">10.1007/s11095-019-2671-y</article-id>
<article-id pub-id-type="manuscript">NIHMS1054651</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Article</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Repurposing Approved Drugs as Inhibitors of K<sub>v</sub>7.1 and Na<sub>v</sub>1.8 To Treat Pitt Hopkins Syndrome</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Ekins</surname>
<given-names>Sean</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Gerlach</surname>
<given-names>Jacob</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Zorn</surname>
<given-names>Kimberley M.</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Antonio</surname>
<given-names>Brett M.</given-names>
</name>
<xref ref-type="aff" rid="A2">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Lin</surname>
<given-names>Zhixin</given-names>
</name>
<xref ref-type="aff" rid="A2">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Gerlach</surname>
<given-names>Aaron</given-names>
</name>
<xref ref-type="aff" rid="A2">2</xref>
</contrib>
</contrib-group>
<aff id="A1"><label>1</label>Collaborations Pharmaceuticals, Inc., 840 Main Campus Drive, Lab 3510, Raleigh, NC 27606, USA.</aff>
<aff id="A2"><label>2</label>Icagen, Inc., 4222 Emperor Blvd, Durham, NC 27703, USA.</aff>
<author-notes>
<corresp id="CR1"><label>*</label>To whom correspondence should be addressed. <email>sean@collaborationspharma.com</email>, Phone: 215-687-1320</corresp>
<fn fn-type="COI-statement" id="FN1">
<p id="P28">Competing interests:</p>
<p id="P29">S.E. is owner, and K.M.Z., are employees of Collaborations Pharmaceuticals Inc. J.G. was an intern at Collaborations Pharmaceuticals Inc. A.G., B.A. and Z.L. are employees of Icagen.</p>
</fn>
</author-notes>
<pub-date pub-type="nihms-submitted">
<day>12</day>
<month>10</month>
<year>2019</year>
</pub-date>
<pub-date pub-type="epub">
<day>22</day>
<month>7</month>
<year>2019</year>
</pub-date>
<pub-date pub-type="collection">
<day>22</day>
<month>7</month>
<year>2019</year>
</pub-date>
<pub-date pub-type="pmc-release">
<day>22</day>
<month>7</month>
<year>2020</year>
</pub-date>
<volume>36</volume>
<issue>9</issue>
<fpage>137</fpage>
<lpage>137</lpage>
<!--elocation-id from pubmed: 10.1007/s11095-019-2671-y-->
<abstract id="ABS1">
<sec id="S1">
<title>Purpose:</title>
<p id="P1">Pitt Hopkins Syndrome (PTHS) is a rare genetic disorder caused by mutations of a specific gene, transcription factor 4 (TCF4), located on chromosome 18. PTHS results in individuals that have moderate to severe intellectual disability, with most exhibiting psychomotor delay. PTHS also exhibits features of autistic spectrum disorders, which are characterized by the impaired ability to communicate and socialize. PTHS is comorbid with a higher prevalence of epileptic seizures which can be present from birth or which commonly develop in childhood. Attenuated or absent TCF4 expression results in increased translation of peripheral ion channels K<sub>v</sub>7.1 and Na<sub>v</sub>1.8 which triggers an increase in after-hyperpolarization and altered firing properties.</p>
</sec>
<sec id="S2">
<title>Methods:</title>
<p id="P2">We now describe a high throughput screen (HTS) of 1280 approved drugs and machine learning models developed from this data. The ion channels were expressed in either CHO (K<sub>V</sub>7.1) or HEK293 (Na<sub>v</sub>1.8) cells and the HTS used either <sup>86</sup>Rb<sup>+</sup> efflux (K<sub>V</sub>7.1) or a FLIPR assay (Na<sub>v</sub>1.8).</p>
</sec>
<sec id="S3">
<title>Results:</title>
<p id="P3">The HTS delivered 55 inhibitors of K<sub>v</sub>7.1 (4.2% hit rate) and 93 inhibitors of Na<sub>v</sub>1.8 (7.2% hit rate) at a screening concentration of 10 Î¼M. These datasets also enabled us to generate and validate Bayesian machine learning models for these ion channels. We also describe a structure activity relationship for several dihydropyridine compounds as inhibitors of Na<sub>v</sub>1.8.</p>
</sec>
<sec id="S4">
<title>Conclusions:</title>
<p id="P4">This work could lead to the potential repurposing of nicardipine or other dihydropyridine calcium channel antagonists as potential treatments for PTHS acting via Na<sub>v</sub>1.8, as there are currently no approved treatments for this rare disorder.</p>
</sec>
</abstract>
<kwd-group>
<kwd>high throughput screen</kwd>
<kwd>K<sub>v</sub>7.1</kwd>
<kwd>Na<sub>v</sub>1.8</kwd>
<kwd>Pitt Hopkins Syndrome</kwd>
<kwd>repurposing</kwd>
</kwd-group>
</article-meta>
</front>
</article>
</pmc-articleset>